COVID-19 vaccinations freeze up the premium vaccine market
By Chon, Seung-Hyun | translator Alice Kang
21.12.02 06:19:36
°¡³ª´Ù¶ó
0
Shingles vaccine market reduced 47% YoY¡¦ Pneumococcal vaccine market reduced 70% YoY
Affected by the prioritization given to COVID-19 vaccinations
But market for cervical cancer vaccines show growth
The premium vaccine market that consists of vaccines used to prevent diseases like shingles, pneumococcal vaccines, etc has contracted greatly. Analysts believe that the demand for other vaccines had decreased due to medical institutions prioritizing COVID-19 vaccinations. However, the cervical cancer vaccine market continued to show growth due to the increase in demand for Gardasil 9.
On the 1st, according to the medical research institution IQVIA, the shingles vaccine market size in Q3 was ₩8.9 billion, down 56.1% from the same period of last year. The cumulative sales by Q3 in the market was ₩29 billion, also a 47.3% drop from last year.
Currently, two products - MSD's ¡®Zosta
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)